60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
60 Degrees Pharmaceuticals(US:SXTP) Globenewswire·2025-12-29 13:01Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced ...